Two-stage hepatectomy after autologous CD133+ stem cells administration: a case report
| Autor: | Letizia Barbieri, Laura Briani, Gabor Panyor, Eloisa Franchi, Marcello Maestri, Andrea Peloso, Paolo Dionigi, M.C. Canepa |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
medicine.medical_specialty Colorectal cancer medicine.medical_treatment Case Report Stem cells Liver metastases Portal vein embolization Surgical oncology Antigens CD medicine Hepatectomy Humans AC133 Antigen Liver surgery Neoadjuvant therapy Glycoproteins business.industry Lymphoma Non-Hodgkin Liver Neoplasms Cancer Middle Aged medicine.disease Prognosis Combined Modality Therapy Liver regeneration Neoadjuvant Therapy Lymphoma Surgery Liver Regeneration Colon cancer Oncology Colonic Neoplasms Stem cell business Peptides Tomography X-Ray Computed Stem Cell Transplantation |
| Zdroj: | World Journal of Surgical Oncology |
| ISSN: | 1477-7819 |
| Popis: | Liver resection is the mainstay of treatment for patients with primary and metastatic liver tumors. However, a large majority of patients present for initial medical evaluation with primary and metastatic liver tumors when their cancer is unresectable. Several trials have been undertaken to identify alternative treatments and complementary therapies. In the near future, the field of liver surgery will aim to increase the number of patients that can benefit from resection, since radical removal of the tumor currently provides the sole chance of cure. This paper reports the case of a patient with an advanced colonic cancer in the era of stem cell therapyIn 2011, a 57 years old white Caucasian man with a previous history of non-Hodgkin lymphoma (NHL) was diagnosed with colon cancer and bilobar liver metastases. Following neoadjuvant therapy, the patient was enrolled in a protocol of stem cell administration for liver regeneration. Surgery was initially performed on the primary cancer and left liver lobe. An extended right lobectomy to S1 was then performed after a portal vein embolization (PVE) and stem cell stimulation of the remaining liver. The postoperative course was uneventful and the patient was free of disease after 12 months. Extreme liver resection can provide a safer option and a chance of cure to otherwise unresectable patients when liver regeneration is boosted by PVE and stem cell administration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink